RIVA-ESCITALOPRAM TABLET

Maa: Kanada

Kieli: englanti

Lähde: Health Canada

Aktiivinen ainesosa:

ESCITALOPRAM (ESCITALOPRAM OXALATE)

Saatavilla:

LABORATOIRE RIVA INC.

ATC-koodi:

N06AB10

INN (Kansainvälinen yleisnimi):

ESCITALOPRAM

Annos:

15MG

Lääkemuoto:

TABLET

Koostumus:

ESCITALOPRAM (ESCITALOPRAM OXALATE) 15MG

Antoreitti:

ORAL

Kpl paketissa:

30/100/500

Prescription tyyppi:

Prescription

Terapeuttinen alue:

SELECTIVE-SEROTONIN REUPTAKE INHIBITORS

Tuoteyhteenveto:

Active ingredient group (AIG) number: 0150435003; AHFS:

Valtuutuksen tilan:

CANCELLED PRE MARKET

Valtuutus päivämäärä:

2020-10-16

Valmisteyhteenveto

PRODUCT MONOGRAPH
PR
RIVA-ESCITALOPRAM
Escitalopram Oxalate Tablets
5 mg, 10 mg, 15 mg, 20 mg as Escitalopram
ANTIDEPRESSANT / ANTIOBSESSIONAL
LABORATOIRE RIVA INC
660 Industriel Blvd.
Blainville, Quebec
J7C 3V4
Date of Revision:
October 03, 2016
www.labriva.com
SUBMISSION CONTROL NO.: 198430
158
_RIVA-ESCITALOPRAM Product Monograph _
_Page 2 of 57_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS
..................................................................................................11
DRUG INTERACTIONS
..................................................................................................24
DOSAGE AND ADMINISTRATION
..............................................................................30
OVERDOSAGE
................................................................................................................32
ACTION AND CLINICAL PHARMACOLOGY
............................................................33
STORAGE AND STABILITY
..........................................................................................35
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................35
PART II: SCIENTIFIC INFORMATION
................................................................................37
PHARMACEUTICAL INFORMATION
..........................................................................37
CLINICAL TRIALS
..........................................................................................................38
DETAILED PHARMACOLOGY
...